Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalteparin for VTE in Cancer Patients
NCT00942968Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 4, open-label, single-arm trial of dalteparin in venous thromboembolism (VTE), sponsored by Pfizer. Primary endpoints: Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee and Number of Participants With New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee. Started Jun 2009; status: completed.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00942968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942968.